Gilead Sciences, Inc.
NEWS
For years, companies have struggled to develop treatments for non-alcoholic fatty liver disease (NAFLD), a disease that is growing across the world and is predicted to become the main cause of chronic liver problems and the need for liver transplantation.
A generic version of Gilead’s Truvada for PrEP is due on the market next year. The activists argue that will be a better alternative price wise.
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
“We are pleased to be working on this program with Gilead given their expertise and global leadership in the HIV and HBV fields,” stated James E. Brown, president and chief executive officer of DURECT.
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
Pharma and biotech companies from across the globe expand their leadership teams and boards.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Daniel O’Day took over the reins of Gilead Sciences in March and has been building his team of lieutenants.
JOBS
IN THE PRESS